8 August 2023
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client, Numab Therapeutics ("Numab"). The project involves PKPD modelling in support of one of Numab's clinical programs and follows on from earlier work conducted by Physiomics on the same asset. The project will span two years of the clinical program.
Physiomics CEO, Dr Jim Millen, commented: "We are delighted that we have a further opportunity to support Numab with its exciting clinical pipeline and look forward to working once again with their talented team."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies. Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 50 targets, and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
